Organization

General Hospital of Ningxia Medical University

20 clinical trials

3 abstracts

Abstract
Nimotuzumab in combination with radiotherapy for elderly patients with locally advanced cervical squamous cell carcinoma: Results from a prospective, multicenter, open-label, single-arm trial.
Org: Zhangzhou Hospital Affiliated to Fujian Medical University, The First Affiliated Hospital of Xi’an Jiaotong University, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Yantai Yuhunagding Hospital, The Affiliated Hospital of Southwest Medical University,
Abstract
Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive metastatic breast cancer: Final results from the phase 2 ICU trial.
Org: Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Breast Medicine Service, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China,
Abstract
Molecular characteristics of KRAS mutations in Chinese patients with cancer.
Org: General Hospital of Ningxia Medical University, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China,